Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 19, 2021 at 09:01 am EST
Share
Endonovo Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 0.00779 million compared to USD 0.03998 million a year ago. Net loss was USD 1.52 million compared to USD 1.07 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.07 a year ago.
For the nine months, sales was USD 0.072789 million compared to USD 0.154296 million a year ago. Net loss was USD 5.5 million compared to net income of USD 1.63 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to basic earnings per share from continuing operations of USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.15 a year ago.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
ENDONOVO THERAPEUTICS, INC. 
